Abstract 4354
Background
Patients’ perception of clinical trials in Poland is mostly influenced by mass media. The image of CTs is often biased which may have an impact on recruitment.
Methods
Based on an anonymous 25-item Paper and Pencil Interview (PAPI) survey among 191 hospitalized oncological patients we analyzed knowledge, perception, willingness to participate and future expectations of CTs. Nominal scale: Yes/No/Don’t know, Likert scale of 0-5 points and multiple choice questions were applied.
Results
The majority of respondents were: (1) women: 70,2%, (2) people with secondary education: 57,6%, (3) at the age of 60-69: 41,9%, (4) living in cities over 100k inhabitants: 46,1%. Main findings 49,2% of respondents agreed to be enrolled in CTs; 15,3% refused and 35,4% were not certain. Among the driving factors for “YES” were: chance for a better/constant care - 76,3% and access to additional monitoring - 73,1%. 57,0% of respondents declared altruistic reason. The main reasons for not participating were: concern about toxicity - 62,1%, lack of efficacy - 55,2% and being a “guinea pig” - 41,4%. Among respondents uncertain about participation in CT, the factors of the highest impact on potential enrollment were: terminal phase of the disease/no other option: 68,7%/ 56,7%. The incentive of the family member or friend does not have a significant impact - only 19,4% respondents would follow it. Other findings 55,8%/ 54,7% of respondents do not know about the existence of any legal acts/state institutions that oversee CTs. 60,8% of respondents do not know whether there are independent bioethical committees that approve each CT prior to launch. 64,9% of respondents think that research funded by pharma companies is NOT as reliable as that of independent sources eg. medical universities. 76,2% of respondents think that the current amount of information on CTs is insufficient and 87,2% would like to know more.
Conclusions
The level of knowledge about CTs among patients is insufficient but the willingness to participate is high which is mainly driven by a possibility of a better and constant care. The trust in the pharmaceutical industry should be increased.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Kotowski: Full / Part-time employment: Roche Polska sp z o.o. All other authors have declared no conflicts of interest.
Resources from the same session
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract